Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Leucyl-tRNA synthetase is a tumor suppressor in breast cancer and enables tumor suppressive translation

ABSTRACT: In this study, we identify leucyl-tRNA synthetase (LARS) as a breast tumor suppressor. To identify the mechanism underlying LARS-mediated breast tumor suppression, we conducted TMT-proteomics in PyMT mouse tumors with monoallelic genetic deletion of LARS in the mammary tumor compartment. The analyses implicate LARS as a regulator of leucine-rich protein translation resulting in downregulation of candidate leucine-rich tumor suppressor genes.

INSTRUMENT(S):

ORGANISM(S): Mus Musculus (mouse)

SUBMITTER: Soren Heissel

LAB HEAD: Sohail Tavazoie

PROVIDER: PXD026609 | Pride | 2022-01-10

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	MS216677LUM_Maria_Tavazoie_Fraction_0.msf	Msf
	MS216677LUM_Maria_Tavazoie_Fraction_01.raw	Raw
	MS216677LUM_Maria_Tavazoie_Fraction_02.raw	Raw
	MS216677LUM_Maria_Tavazoie_Fraction_03.raw	Raw
	MS216677LUM_Maria_Tavazoie_Fraction_04.raw	Raw

Items per page:

1 - 5 of 9

Similar Datasets

Charged tRNA profiling of mcf10a, HCC1806 cells, polysome profiling, RNA-Seq and Ribo-Seq in 4T07 cells upon LARS knockdown by shRNA, and RNA-Seq of ribosome-associated RNAs in Lars depleted PyMT tumors

Project description:In this study, we identify leucyl-tRNA synthetase (LARS) as a breast tumor suppressor. To identify the mechanism underlying LARS-mediated breast tumor suppression, we first conducted charged tRNA profiling to assess charged and total tRNA-Leu expression in cell lines with high and low LARS expression. Expression of select charged and total tRNA-Leu isoacceptors were reduced in cell lines with lower LARS expression. We then conducted RNA-Seq and translation profiling including ribosome profiling (Ribo-Seq), polysome profiling in LARS-depleted cell lines. To test our hypothesis in vivo, we also performed RNA-Seq of ribosome-associated RNAs in Lars depleted PyMT tumors within RiboTag mice. The analyses implicate LARS as a regulator of leucine-rich translation.

2022-01-05 | GSE176130 | GEO

KANK1 inhibits the tumor suppressor Scribble by competing for NOS1AP binding

Project description:KANK1 belongs to the KANK family of scaffolding proteins that is expressed in epithelial cells and connects focal adhesions with the adjacent cortical microtubule stabilizing complex. Although KANK1 overexpression studies was shown to suppress the growth of different cancer cell lines in vitro, The Cancer Genome Atlas (TCGA) database indicates that high rather than low KANK1 levels are associated with poor prognosis in a wide spectrum of human malignancies. In the present study, we addressed this discrepancy and characterized how KANK1 regulates tumor development in the Polyoma Middle T (PyMT)-driven murine breast cancer model and upon orthotopic implantation of human breast cancer cells in immune-deficient mice. Our results revealed that KANK1 promotes cell proliferation and cell survival of PyMT-transformed tumor cells in vivo. Mechanistically, KANK1 localizes to the basal side of basement membrane (BM)-attached transformed luminal epithelial cells. However, when these cells detach from the BM and disassemble integrin adhesions, KANK1 translocates to cell-cell junctions where it competes with the polarity and tumor suppressor protein SCRIB for NOS1AP binding and thereby curbs the ability of SCRIB to activate the Hippo pathway. The consequences are stabilization and nuclear accumulation of TAZ, growth and survival of tumor cells and elevated breast cancer development. Importantly, the oncogenic pathway induced by KANK1 at cell-cell junctions also operates in human breast cancer.

2024-09-24 | PXD049122 | Pride

Biomarkers of residual disease, disseminated tumor cells, and metastases in the MMTV-PyMT breast cancer model

Project description:Gene expression profiling of disseminated tumor cells in lung, lung metastatses and residual tumor cells in the MMTV-PyMT breast cancer model. Profiling gene expression change between disseminated tumor cells, lung metastases and residual tumor cells from the MMTV-PyMT breast cancer model.

2013-01-18 | E-GEOD-43566 | biostudies-arrayexpress

Consequences of sEH deletion in the polyoma middle T (PyMT) breast cancer tumor proteome

Project description:The aim of this investigation was to study the consequences of interfering with soluble epoxide hydrolase (sEH) expression on tumor growth and metastasis in genetically modified animals that spontaneously generate tumors without the exogenous application of high concentrations of epoxide mediators or inhibitors. Therefore, breast cancer development was studied in mice expressing the polyoma middle T oncogene (PyMT) under the control of the mouse mammary tumor virus promoter, to induce spontaneous mammary tumors. To facilitate the study of endogenous sEH activity in tumor growth, PyMT mice were then crossed with sEH-/- mice to generate sEH-deficient mice that spontaneously generate breast tumors (so called PyMTsEH mice). For these analyses, primary tumors were removed from 20 week old mice.

2021-09-14 | PXD026214 | Pride

Homo sapiens

Project description:Epigenetically regulated Fibronectin leucine rich transmembrane protein 2 (FLRT2) shows tumor suppressor activity in breast cancer cells

| PRJNA337938 | ENA

Dll1 dependent heterogeneity of tumor and cancer fibroblasts

Project description:To survey the diverse tumor cell populations of aggressive luminal breast cancer (non-TNBC) at a cellular level, we utilized Dll1+ and Dll1- tumors from a recently published PyMT-Dll1mCherry reporter breast cancer mouse model.

2022-08-14 | GSE182011 | GEO

Biomarkers of residual disease, disseminated tumor cells, and metastases in the MMTV-PyMT breast cancer model

Project description:Gene expression profiling of disseminated tumor cells in lung, lung metastatses and residual tumor cells in the MMTV-PyMT breast cancer model.

2013-01-18 | GSE43566 | GEO

Single-cell RNA-seq of Ecad positive PyMT bulk tumor cells

Project description:In this study we studied the presence of tumor cells that underwent epithelial-to-mesenchymal transition within polyoma middle T antigen (PyMT) breast tumors. For this we dissociated tumors and isolated Ecad positive tumor cells by FACS sorting. We confirmed that PyMT tumors contain a small set of tumor cells that have undergone EMT in the primary tumor and that E-cadherin can be used as a marker on single cell level for mesenchymal status in this model. We isolated primary tumors from mice, dissociated the tumors and FACS-sorted for single Ecad positive tumor cells, after this we performed single cell sequencing of the cells.

2016-03-09 | E-GEOD-77107 | biostudies-arrayexpress

Transformation of enriched mammary cell populations with Polyoma Middle T Antigen influences tumor subtype and metastatic potential

Project description:Breast cancer is a multifaceted disease, exhibiting significant molecular, histological, and pathological diversity. Factors that impact this heterogeneity are poorly understood; however, transformation of distinct normal cell populations of the breast may generate different tumor phenotypes. Our previous study demonstrates that the polyomavirus middle T antigen (PyMT) oncogene can establish diverse tumor subtypes when broadly expressed within mouse mammary epithelial cells. Herein, we assess the molecular, histological, and metastatic outcomes from distinct mammary cell populations transformed with PyMT. By combining several methodologies, including lentiviral infection, cell sorting, and transplantation, we have characterized tumors arising from enriched populations of mammary epithelial cells. We have found that expression of PyMT within different cell populations influences tumor histology, molecular subtype, and metastatic potential. 32 samples, 1 from each of 32 mouse mammary tumors arising from transplanted mouse mamary epithelial cells (MMECs) transduced with PyMT-expressing lentivirus. MMECs were sorted into four different types prior to transplant: luminal CD133+ (8 samples), luminal CD133- (11 samples), stem (6 samples), and basal (7 samples). The background for the cell donor and transplant recipients mice was FVB/NJ obtained from Jackson Laboratories.

2015-09-08 | E-GEOD-64453 | biostudies-arrayexpress

CXCL12 restricts tumor growth by suppressing the Ras, ERK1/2, c-Myc and the immune checkpoint PDL1 pathways

Project description:Cytokines constitute a family of proteins that are secreted by a broad variety of cells and modulate the immune response. CXCL12, along with its receptor CXCR4, are essential players in numerous biological processes. Dysregulation of their function can underlie the mechanisms(s) of several pathologies, including malignancies. Here, we demonstrate a rather unexpected effect of the cytokine and its receptor: in both cells and animal models, CXCL12 restricts tumorigenicity of the glioblastoma cells U87-MG and U-118, and of the breast cancer cell PyMT. Overexpression of CXCL12 inhibits activation of the proto-oncogene Ras which results in downregulation of its proliferative signals, such as reduced phosphorylation of the extracellular signal-regulated kinase 1/2 (ERK1/2), inhibition of c-Myc expression, and subsequent inhibition of cell cycle. Furthermore, CXCL12 induces downregulation of the growth differentiation factor 15 (GDF15), insulin-like growth factor-binding protein 6 (IGFBP6), and matrix metalloproteinase-3 (MMP3), which are implicated in the metastatic process. Indeed, monitoring cell migration in vitro and generation of metastases in mice demonstrate that CXCL12 slows the migration of U87-MG and PyMT cells. Remarkably, overexpression of CXCL12 also downregulates the cell surface immune checkpoint protein programmed cell death-ligand 1 (PDL1), as is evidence by enhanced recruitment of cytotoxic CD8 T cells. Overall, CXCL12 inhibits tumor growth through several distinct mechanisms: inhibition of cell cycle and migration, as well as impairment of immune checkpoint, thereby stimulating a strong host’s immune response. The mechanism(s) that renders CXCL12 a tumor promoting agent in certain cells, and a tumor suppressor in others has remained elusive.

2024-11-28 | PXD054783 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data